Main Article Content

Abstract

ABSTRACT
Introduction. The first line regimen of treatment of Helicobacter pylori (H. pylori) in Africa is not consensual. Protocols used are issued from European recommendations, while the bacteria types are different and antibiotic sensibilities are not the same. The goal of this study was to describe the first line regimen used to treat H. pylori in a sub-Saharan country, to evaluate its efficacy and to identify factors associated with a non-response. Methods. we have conducted a descriptive cross sectional study from January to May 2019 in three medical centers of Yaoundé (Cameroon). We have included all adult patients who have realized a gastroscopy which has proven the H. pylori infection naïve from any prior eradication treatment. Results. Protocols used were the concomitant quadri therapy (a proton pump inhibitor, clarithromycin, amoxicillin and metronidazole) for 14 days or a sequential treatment a proton pump inhibitor and amoxicillin for the first 5 days, followed by proton pump inhibitor, clarithromycin, and metronidazole for another 5 days). We found a global success of 73.9% (with 78.8% for the concomitant quadri therapy and 65.6% for the sequential treatment. Factors associated with a non-response to the treatment were the poor observance and the low educational level. Conclusion. the first-line treatment of H. pylori is based on quadri therapy sequential or concomitant with a global success of 73.9%.

Article Details

How to Cite
Ndjitoyap Ndam, A. W., Mathurin KOWO, Winnie BEKOLO NGA, André ATANGANA MESSI, Paul TALLA, Georges BOUGHA, TAGNI SARTRE, M. . ., BIWOLE SIDA, M. ., Elie Claude NDJITOYAP NDAM, Firmin ANKOUANE ANDOULO, & Oudou NJOYA. (2021). Efficacy of the first line regimen of treatment for Helicobacter pylori in a sub-Saharan country. HEALTH SCIENCES AND DISEASE, 22(11). Retrieved from https://hsd-fmsb.org/index.php/hsd/article/view/3070

References

  1. Agbor, N.E., et al., Helicobacter pylori in patients with gastritis in West Cameroon: prevalence and risk factors for infection. BMC Res Notes, 2018. 11(1): p. 559.
  2. Diomande, M.I., et al., [Chronic gastritis and Helicobacter pylori infection on the Ivory Coast. A series of 277 symptomatic patients]. Gastroenterol Clin Biol, 1991. 15(10): p. 711-6.
  3. Kouitcheu Mabeku, L.B., M.L. Noundjeu Ngamga, and H. Leundji, Helicobacter pylori infection, a risk factor for Type 2 diabetes mellitus: a hospital-based cross-sectional study among dyspeptic patients in Douala-Cameroon. Sci Rep, 2020. 10(1): p. 12141.
  4. Ankouane, F., et al., Helicobacter pylori and precancerous conditions of the stomach: the frequency of infection in a cross-sectional study of 79 consecutive patients with chronic antral gastritis in Yaounde, Cameroon. Pan Afr Med J, 2015. 20: p. 52.
  5. Lee, H., et al., Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial. Trials, 2017. 18(1): p. 549.
  6. Abdulkhakov, S.R., et al., [European Registry on the management of Helicobacter pylori infection: features of diagnosis and treatment in Kazan]. Ter Arkh, 2020. 92(8): p. 52-59.
  7. Apostolopoulos, P., et al., 10-Day Versus 14-Day Quadruple Concomitant Nonbismuth Therapy for the Treatment of Helicobacter pylori Infection: Results From a Randomized Prospective Study in a High Clarithromycin Resistance Country. J Clin Gastroenterol, 2020. 54(6): p. 522-527.
  8. Zagari, R.M., et al., Treatment of Helicobacter pylori infection: a clinical practice update. Minerva Med, 2020.
  9. Linz, B., et al., Population genetic structure and isolation by distance of Helicobacter pylori in Senegal and Madagascar. PLoS One, 2014. 9(1): p. e87355.
  10. Kouitcheu Mabeku, L.B., et al., Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates. BMC Infect Dis, 2019. 19(1): p. 880.
  11. Dia, D., et al., [Helicobacter pylori and gastroduodenal lesions in Dakar, Senegal]. Med Trop (Mars), 2010. 70(4): p. 367-70.
  12. Eloumou Bagnaka, S.A., et al., [Risk factors associated with gastroduodenal lesions in a Douala referral hospital (Cameroon)]. Med Sante Trop, 2016. 26(1): p. 104-9.
  13. Mbengue, M., et al., [Frequency of Helicobacter pylori infection in symptomatic patients in Senegal]. Med Trop (Mars), 1997. 57(3): p. 256-8.
  14. Peretz, A., et al., An efficiency comparison between three invasive methods for the diagnosis of Helicobacter pylori infections: Culture from stomach biopsy, rapid urease test (CUTest((R))), and histologic examination of gastric biopsy. Ann Clin Lab Sci, 2015. 45(2): p. 148-51.
  15. Bang, C.S., et al., Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection. Gut Microbes, 2020. 11(5): p. 1314-1323.
  16. Megraud, F., et al., Survey of the antimicrobial resistance of Helicobacter pylori in France in 2018 and evolution during the previous 5 years. Helicobacter, 2021. 26(1): p. e12767.
  17. Ducournau, A., et al., Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods. Clin Microbiol Infect, 2016. 22(8): p. 715-8.
  18. Seck, A., et al., Antibiotic susceptibility of Helicobacter pylori isolates in Dakar, Senegal. J Infect Dev Ctries, 2009. 3(2): p. 137-40.

Most read articles by the same author(s)

1 2 > >>